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A B S T R A C T
Objectives: To identify factors associated with high-risk human papillomavirus (HPV) infection and high grade
squamous intraepithelial lesion (HSIL) among a high-risk group of HPV-unvaccinated women in Montevideo.
Methods: Participants completed a questionnaire on socio-demographics, sexual behavior and gynecological
history and received a gynecological examination. HPV DNA was detected by PCR using MY09/11 primers.
Logistic regression analyses were performed to identify factors associated with high-risk HPV infection and HSIL.
Results: A total of 469 women with HPV DNA and cytological results completed the questionnaire. Among
women older than 30 years, those with high number of sexual partners and regular housing conditions were
more likely to be positive for high-risk HPV infection (adjusted OR: 2.94, 95%CI: 1.01–8.51 and 2.68, 95%CI:
1.01–7.21, respectively). A marginally non-statistically significant association between getting a HSIL and
having a high number of sexual partners was also observed (adjusted OR: 3.22, 95%CI: 0.97–10.75).
Conclusions: In an era of development of new strategies for accelerating the reduction of cervical cancer in-
cidence and mortality, our results may contribute to identify populations most susceptible to get benefit from
broadening the scope for prevention of cervical cancer and could be used with other triage strategies.
1. Introduction
Cervical cancer is the third most common malignancy among
women worldwide. Defined as disease of disparity, wide variations are
observed between high- and low-burden countries, with incidence rates
ranging from< 3 to> 50 per 100,000 [1]. The marked regional dif-
ferences in incidence of cervical cancer are not only due to differences
on screening programs but also to different exposure to risk factors.
Thus, getting information about factors associated to getting a high
grade cervical lesion or an infection with high-risk human papilloma-
viruses (HPV) – the necessary cause to develop cervical cancer [2] – is
relevant when formulating appropriate cervical cancer control
strategies.
Central and South America (CSA) region has some of the highest
cervical cancer incidence and mortality rates [1]. In Uruguay, cervical
cancer is the third most common cancer among women with 402 new
cervical cancer cases and 175 cervical cancer deaths estimated annually
and age-standardized incidence and mortality rates of 19.0 and 7.1 per
100.000 women respectively [1]. Despite the figures are among the
lowest in the region, yet they are considerably higher than those found
in relatively low burden countries such as United States with 6.6 new
cases and 2.7 new deaths per 100,000 women [1]. Moreover, the dis-
ease acquires a particular significance in the country given the socio-
economic characteristics of the affected population [3].
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HPV infection is one of the most common sexually transmitted in-
fections (STI) worldwide. The estimated HPV prevalence among women
with normal cytology is 11.7% worldwide and 16.1% in CSA [4]. HPV
testing has been proven as an effective complementary tool for cervical
cancer screening [5]. Moreover, it is starting to be recommended as
primary testing, in line with available evidence showing that HPV
testing is more efficacious than screening based on cytology [6,7]. Since
2007, two prophylactic vaccines are available to protect against infec-
tion with the two most common high-risk genotypes in cervical cancer,
HPV16/18 [8], which are responsible for 70% of all cervical cancer
cases [9]. Moreover, a second generation nona-valent vaccine pro-
tecting against infection with HPV6/11/16/18/31/33/45/52/58 has
also been approved [10].
The development of new and effective cervical cancer prevention
tools raise opportunities for new approaches for accelerating the re-
duction of cervical cancer incidence and mortality, such as combining
both HPV screening and vaccination [11]. In this context is of particular
interest to identify populations most susceptible to get benefit from
broadening the scope for prevention of cervical cancer.
In the last years there has been in Uruguay an increasing public
health concern about cervical cancer control. Opportunistic screening
was initiated in 1994 with a recommendation of an annual cytology
regardless of age [3]. This recommendation was later revised [12]. In
2013, the Ministry of Health launched a cervical cancer awareness
campaign and free vaccination was made available for 12 years-old
girls [13]. Yet, epidemiological knowledge about HPV in the country
was not available since a recent study presented results on HPV pre-
valence and genotype distribution in 568 women attending the cervical
screening clinics of the National Cervical Cancer Prevention Sub-Pro-
gram [14]. Shortly after, two additional studies reported on HPV pre-
valence and type distribution in invasive cervical cancer [15] and in
women with and without cervical intraepithelial lesions [16] obtaining
similar results than the first study [14].
We present here the results on the factors associated with having a
high-risk HPV infection or a high grade squamous intraepithelial lesion
(HSIL) among women participating in the previous study [14] in order
to provide relevant information for the design of appropriate strategies
towards cervical cancer control in Uruguay.
2. Methods
This was a cross-sectional study, previously explained in Ramas
et al. [14]. Briefly, the program was led by the Montevideo city hall.
Women attending the cervical screening public clinics of the National
Cervical Cancer Prevention Sub-Program were invited to participate in
the study if they were not pregnant, not having a previous history of
neoplastic disease and not been vaccinated against HPV. Since the study
population was considered a high-risk population, it was decided to
include all women requesting a PAP test without age restrictions de-
spite the program recommendation of starting screening at age 21. A
general gynecological examination was conducted for all participants,
who were previously invited to complete a self-administered standar-
dized questionnaire. Smears were cytologically diagnosed according to
the Bethesda classification system, and confirmed by histology in case
of squamous intraepithelial lesion any grade results. The cytology was
made without knowledge of HPV results.
Sample processing and HPV DNA detection and genotyping was
performed as previously described [14]. Briefly, HPV DNA was detected
by PCR using MY09/11 primer set and genotyping was performed by
restriction enzyme digestion of PCR products (RFLP assay).
The questionnaire was completed by the participants prior to the
gynecological examination. It had 17 questions divided into three sec-
tions. The first section had six sociodemographic items: age, educa-
tional level, designated primary care center, building material of the
house, type of bathroom, access to safe water and sanitation services.
The second section had six questions about gynecological history:
number of pregnancies, age at first sexual intercourse, age at first
pregnancy, number of sexual partners in the last year, number of living
children and date of last gynecological examination. The third section
had five items about associated risk factors: previous history of STI,
contraceptive use, type of contraceptive, time of use, and smoking
history.
A new variable – housing conditions – was constructed from the
following variables: 1) access to safe water and sanitation services, 2)
type of bathroom and, 3) house building material. Each category was
scored from 0 to 2 points. The variable “housing conditions” was the
sum of all of them. A score of six was considered “good” and a score
lower than six was classified as “regular”. The city of Montevideo has
eight districts (A, B, C, CH, D, E, F, G). To define the variable district
zone by percentage of poverty (stratified by:< 5% low, 5–15% medium
and>15% high) official data census and classifications of the
Household Survey of Municipality of Montevideo 2012 were used. The
concept of poverty had been previously built using the per capita
household income value compared with the price of a standard basket
of food [17]. The women were classified as living in one district ac-
cording to their designated primary care center.
Quantitative variables were described using the mean (with stan-
dard deviation, SD); qualitative variables were described using per-
centages. Univariate and multivariate logistic regression models were
performed to identify possible factors associated with the presence of
HSIL among all women, and of high-risk HPV infection among women
aged 30 or more. Women younger than 30 years were excluded from
the latter analysis given the high HPV prevalence and the fact that most
infections regress spontaneously in this group. Moreover, new ap-
proaches for accelerating the reduction of cervical cancer incidence and
mortality by combining both HPV screening and vaccination propose to
offer HPV vaccination to women aged 25–45 years, with concomitant
HPV-DNA screening in women aged 30 years and above [11]. The
measure of association used was the Odds ratio (ORs) with 95% con-
fidence interval (95%CI). Only the variables that were statistically
significant in the univariate analysis were included in the final multi-
variate logistic regression model.
All volunteer participants gave their written informed consent to
participate in the study. The study was approved by the Faculty of
Medicine's Ethics Committee.
2.1. Role of the funding source
The authors declare that the sponsors did not have any role in the
study design, collection, analysis and interpretation of the data.
3. Results
A total of 469 women with valid HPV DNA and cytological results
completed the questionnaire between October 2008 and December
2010. The age range was 14–70 and the overall mean age (SD) was 33.3
(10.9). More than a third of women (n=183, 39.0%) were younger
than 30 years old. Most of participants had their first sexual intercourse
before the age of 15 (63.8%) whereas 17.1% reported not having had a
sexual partner or only one in the last twelve months. The most common
number of full-term pregnancies was two, and 22.6% of the women had
their first children before the age of 18. Almost a third of women had a
university degree, and 41.8% never smoked. Most of participants came
from peripheral districts (A, G, D, E, and F) whereas the representation
of participants from the richest districts (C, B and CH) was low. Almost
half of the women (45.8%) came from districts with percentages of
poverty> 15% (A, D and F).
A total of 224 women (47.8%; 95%CI: 43.2–52.4) were negative for
intraepithelial lesion or malignancy (NILM). Prevalence of ASCUS, LSIL
and HSIL were 5.1% (n=24; 95%CI: 3.3–7.5), 35.0% (n: 164; 95%CI:
30.7–39.5) and 12.2% (n: 57; 95%CI: 9.3–15.5), respectively. Overall
high-risk HPV prevalence among all participants was 24.5% (95%CI:
V.-G. Sequera et al. Papillomavirus Research 5 (2018) 122–127
123
Table 1
Association between HSIL cytological result and sociodemographic, sexual and reproductive factors (LSIL and ASCUS excluded).
Variable NILM N=224 (%) HSIL N=57 (%) Crude OR (95%CI) Adjusteda OR (95%CI) p-value for trend
Age (years)
< 30 82 (36.6) 25 (43.9) Ref. –
30 – 39 70 (31.3) 14 (24.6) 0.66 (0.32–1.36) –
40 – 49 54 (24.1) 11 (19.3) 0.67 (0.30–1.47) –
≥ 50 15 (6.7) 6 (10.5) 1.31 (0.46–3.74) –
Missing 3 (1.3) 1 (1.8) 1.09 (0.11–10.98) –
Age of first sexual relationship .639
≥ 15 146 (65.2) 34 (59.6) 1 1
< 15 73 (32.6) 16 (28.1) 0.94 (0.49–1.82) 1.28 (0.60–2.75)
Missing 5 (2.2) 7 (12.3) 6.01 (1.80–20.10) 2.02 (0.42–9.71)
Education
≥High school 65 (29.0) 12 (21.1) Ref. –
< High school 149 (66.5) 39 (68.4) 1.42 (0.70–2.88) –
Missing 9 (4.5) 10 (10.5) 3.25 (0.99–10.63) –
Sexual partners over last year 0.029
0 – 1 50 (22.3) 6 (10.5) Ref. Ref.
2 – 4 99 (44.2) 14 (24.6) 1.17 (0.43–3.25) 1.30 (0.46–3.66)
≥ 5 23 (10.3) 8 (14.0) 2.89 (0.90–9.32) 3.22 (0.97–10.75)
Missing 52 (23.2) 29 (50.9) 4.65 (1.78–12.15) 3.54 (1.20–10.40)
Pap test in the last 3 years
Yes 177 (79.0) 51 (89.5) Ref. –
No 6 (2.7) 1 (1.8) 0.59 (0.07–4.15) –
Missing 41 (18.3) 5 (8.8) 0.43 (0.16–1.13) –
Ever had an STI 0.827
No 151 (67.4) 29 (50.9) Ref. Ref.
Yes 36 (16.1) 8 (14.0) 1.16 (0.49–2.74) 1.01 (0.41–2.52)
Missing 37 (16.5) 20 (35.1) 2.82 (1.44–5.52) 1.31 (0.55–3.12)
Smoke
Never 94 (42.0) 27 (47.4) Ref. –
Former 18 (8.0) 1 (1.8) 0.19 (0.03–1.52) –
Current 96 (42.9) 20 (35.1) 0.73 (0.38–1.38) –
Missing 16 (7.1) 9 (15.8) 1.96 (0.78–4.92) –
Steady partner 0.503
Yes 171 (76.3) 38 (66.7) Ref. Ref.
No 45 (20.1) 11 (19.3) 1.10 (0.52–2.32) 1.03 (0.46–2.28)
Missing 8 (3.6) 8 (14.0) 4.50 (1.59–12.75) 2.08 (0.61–7.10)
Full-term pregnancies
0− 1 64 (28.6) 19 (33.3) Ref. –
2− 3 95 (42.4) 23 (40.4) 0.82 (0.41–1.62) –
≥ 4 50 (22.3) 9 (15.8) 0.61 (0.25–1.46) –
Missing 15 (6.7) 6 (10.5) 1.34 (0.46–3.95) –
Age at first pregnancyb 0.391
≥ 18 125 (58.4) 23 (46.9) Ref. Ref.
< 18 53 (24.8) 13 (26.5) 1.33 (0.63–2.28) 1.62 (0.68–3.87)
Missing 21 (9.8) 8 (16.3) 2.83 (1.26–6.32) 2.06 (0.80–5.33)
Contraceptive use
No 93 (41.5) 21 (36.8) Ref. –
OC 76 (33.9) 21 (36.8) 1.22 (0.62–2.41) –
Any 1 (0.4) 1 (1.8) 4.43 (0.27–73.70) –
Missing 54 (24.1) 14 (24.6) 1.14 (0.54–2.44) –
Years of OC usec
< 1 15 (14.0) 2 (9.5) Ref. –
1− 4 38 (35.5) 5 (23.8) 0.99 (0.17–5.65) –
≥ 5 35 (32.7) 5 (23.8) 1.07 (0.19–6.15) –
Missing 19 (17.8) 9 (42.9) 3.55 (0.67–18.97) –
Housing conditions
Good 39 (17.4) 8 (14.0) Ref. –
Regular 165 (73.7) 44 (77.2) 1.30 (0.58–2.98) –
Missing 20 (8.9) 5 (8.8) 1.22 (0.35–4.21) –
District by poverty rated
Low poverty 40 (17.9) 14 (24.6) Ref. –
Median poverty 57 (25.4) 18 (31.6) 0.90 (0.40–2.02) –
High poverty 105 (46.9) 16 (28.1) 0.44 (0.20–1.00) –
Missing 22 (9.8) 9 (15.8) 1.16 (0.43–3.13) –
Low Grade Squamous Intraepithelial Lesion (LSIL) and Atypical Squamous Cell of Undetermined Significance (ASCUS) excluded from the analysis. HSIL=High
Grade Squamous Intraepithelial Lesion; NILM=Negative for Intraepithelial Lesion or Malignancy;OR=Odd Ratio; STI= sexually transmitted infections; OC=oral
contraceptives.
a Adjusted for significant variables of crude analysis.
b Includes only women with children.
c Includes only OC users.
d < 5% Low. 5–15% Medium and> 15% High.
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Table 2
Association between high-risk HPV infection and sociodemographic. sexual and reproductive factors (women younger than 30 years excluded).
Variable HR-HPV-N=220 (%) HR-HPV+N=66 (%) Crude OR (95%CI) Adjusteda OR (95%CI) p-value for trend
Age (years)
30 – 39 109 (49.5) 37 (56.1) Ref. –
40 – 49 81 (36.8) 16 (24.2) 0.58 (0.30–1.12) –
≥ 50 27 (12.3) 12 (18.2) 1.31 (0.60–2.84) –
Missing 3 (1.4) 1 (1.5) 0.98 (0.10–9.73) –
Age of first sexual relationship
≥ 15 160 (72.7) 49 (74.2) Ref. –
< 15 46 (20.9) 12 (18.2) 0.85 (0.42–1.73) –
Missing 14 (6.4) 5 (7.6) 1.17 (0.40–3.40) –
Education
≥High school 61 (27.7) 13 (19.7) Ref. –
< High school 150 (68.2) 47 (71.2) 1.47 (0.74–2.91) –
Missing 9 (4.1) 6 (9.1) 3.13 (0.95–10.32) –
Sexual partners over last year 0.084
0 – 1 42 (19.1) 7 (10.6) Ref. Ref.
2 – 4 95 (43.2) 22 (33.3) 1.39 (0.55–3.50) 1.44 (0.57–3.65)
≥ 5 25 (11.4) 12 (18.2) 2.88 (1.01–8.28) 2.94 (1.01–8.51)
Missing 58 (26.4) 25 (37.9) 2.59 (1.02–6.54) 2.53 (0.99–6.56)
Pap test in the last 3 years
Yes 183 (83.2) 52 (78.8) Ref. –
No 3 (1.4) 0 (0.0) – –
Missing 34 (15.5) 14 (21.2) 1.45 (0.72–2.90) –
Ever had an STI
No 156 (70.9) 41 (62.1) Ref. –
Yes 29 (13.2) 9 (13.6) 1.18 (0.52–2.69) –
Missing 35 (15.9) 16 (24.2) 1.74 (0.88–3.45) –
Smoke
Never 91 (41.4) 36 (54.5) Ref. –
Former 20 (9.1) 2 (3.0) 0.25 (0.06–1.14) –
Current 89 (40.5) 23 (34.8) 0.65 (0.36–1.19) –
Missing 20 (9.1) 5 (7.6) 0.63 (0.22–1.81) –
Steady partner
Yes 165 (75.0) 47 (71.2) Ref. –
No 48 (21.8) 13 (19.7) 0.95 (0.48–1.90) –
Missing 7 (3.2) 6 (9.1) 3.01 (0.97–9.39) –
Full-term pregnancies
0 – 1 41 (18.6) 11 (16.7) Ref. –
2 – 3 100 (45.5) 39 (59.1) 1.45 (0.68–3.11) –
≥ 4 74 (33.6) 16 (24.2) 0.81 (0.34–1.90) –
Missing 5 (2.3) 0 (0.0) – –
Age at first pregnancyb
≥ 18 154 (71.3) 44 (71.0) Ref. –
< 18 43 (19.9) 9 (14.5) 0.73 (0.33–1.62) –
Missing 19 (8.8) 9 (14.5) 1.66 (0.70–3.92) –
Contraceptive use
No 99 (45.0) 27 (40.9) Ref. –
OC 57 (25.9) 19 (28.8) 1.22 (0.63–2.39) –
Any 1 (0.5) 1 (1.5) 3.67 (0.22–60.56) –
Missing 63 (28.6) 19 (28.8) 1.11 (0.57–2.15) –
Years of OC usec
< 1 5 (8.8) 4 (21.1) Ref. –
1 – 4 14 (24.6) 3 (15.8) 0.27 (0.04–1.64) –
≥ 5 25 (43.9) 6 (31.6) 0.30 (0.06–1.47) –
Missing 13 (22.8) 6 (31.6) 0.58 (0.11–2.95) –
Housing conditions 0140
Good 41 (18.6) 5 (7.6) Ref. Ref.
Regular 160 (72.7) 55 (83.3) 2.82 (1.06–7.49) 2.68 (1.01–7.21)
Missing 19 (8.6) 6 (9.1) 2.58 (0.70–9.55) 2.56 (0.56–8.12)
District by poverty rated
Low poverty 33 (15.0) 12 (18.2) Ref. –
Median poverty 62 (28.2) 28 (42.4) 1.24 (0.56–2.76) –
High poverty 101 (45.9) 24 (36.4) 0.65 (0.30–1.45) –
Missing 24 (10.9) 2 (3.0) 0.23 (0.05–1.12) –
HR-HPV-=Negative for high-risk human papillomavirus; HR-HPV-=Positive for high-risk human papillomavirus; OR=Odd Ratio; STI= sexually transmitted
infections; OC= oral contraceptives.
a Adjusted for significant variables of crude analysis.
b Includes only women with children.
c Includes only OC users.
d < 5% Low. 5–15% Medium and> 15% High.
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20.7–28.7), and among participants aged 30 years or more, 23.1%
(95%CI: 18.3–28.4).
Table 1 shows the results of the univariate and multivariate analyses
on the likelihood of getting a HSIL. After adjusting for age at first sexual
relationship, number of sexual partners over last year, previous history
of STI, having a steady partner and age at first pregnancy, we found that
a high number of sexual partners (i.e. more than five) increased the risk
of HSIL (adjusted OR=3.22, 95%CI: 0.97–10.75). However, this as-
sociation was marginally non-statistically significant. Missing values
categories of variables related to sexual behavior (age at first sexual
relationship, sexual partners over last year, STIs history, having steady
partner and age at first pregnancy) showed a statistical significant as-
sociation with getting a HSIL. Nevertheless, all but a high number of
sexual partners lost the statistical significance in the multivariable
model. Other variables such as education, having had a PAP test in the
last three years, smoking or contraceptive use did not show association
with HSIL.
The association of the different variables with high-risk HPV in-
fection among women older than 30 years (n=286) was also explored
(Table 2). In the univariate analysis, only a high number of sexual
partners and regular housing conditions were found to be associated
with an increased risk of high-risk HPV infection. The association was
still observed in the multivariate analysis for both variables (adjusted
OR: 2.94, 95%CI: 1.01–8.51 and 2.68, 95%CI: 1.01–7.21, respectively).
4. Discussion
This is, to our knowledge, the first study analyzing factors asso-
ciated with high-risk HPV infection and high grade cervical lesions in
Uruguay. Previous studies examined overall HPV prevalence and type
distribution in Uruguayan women with or without cervical lesions
[14–16]. The results of those studies evidenced the relatively high HPV
prevalence in the country as compared with other regions, but the
factors associated with HPV infection had not been yet ascertained.
Overall, one half of our sample presented abnormal cytological re-
sults. This prevalence is considerably higher than those found in other
equivalent studies [15,18,19] and shows a potential high overcalling of
cytology in our sample. However, most of the abnormal cytological
results (35%) were LSIL which most often resolve spontaneously
without needing any kind of intervention and may thus be classified as
normal cytological results. Moreover, our sample was composed mainly
by young women (mean age = 33.3) coming from districts with per-
centages of poverty> 15% (46%). In addition, they might attend the
cervical screening clinics for additional reasons such as seeking con-
traceptive advice or pregnancy confirmation, services which were also
offered for free in the clinics. Thus, they could be considered as a high
risk group where percentages of abnormal cytology are expected to be
higher. The overall prevalence of high-risk HPV infection was 24.5%,
slightly higher than the 20.8% found in a previous study from Uruguay
[15]. Among women 30 years or older, the prevalence of high-risk HPV
infection dropped to 23.1%.
Several studies have analyzed the association between reproductive
factors and cervical carcinoma [20,21]. High parity and early age at
first full-term pregnancy have been shown to increase cervical cancer
risk. However, those factors have not shown a clear pattern regarding
association with HPV infection [22–27]. We did not find a positive
association between reproductive factors and HR-HPV infection or HSIL
in our study. As expected, a high number of sexual partners was found
to be consistently associated with getting a high grade cervical lesion
[28] and a high-risk HPV infection [22,29–31]. Despite the association
between tobacco use and HSIL and high risk-HPV infection is well es-
tablished [30,32], it was not observed in our sample, where prevalence
of tobacco use was high (48%). This could be partially explained by the
fact that the question asking for tobacco use in our study was not ex-
actly formulated in the same way than in population-based tobacco
surveys, which could limit the quality of the data obtained from this
variable. Women aged 30 years old or more living in regular housing
conditions were more likely to be positive for high-risk HPV infection
than those living in good housing conditions. Other socioeconomic
variables such as educational level and district of the city did not show
different outcomes despite those are present in other CSA studies
[19,27–31]. This could be explained by the fact that almost half of our
sample came from districts with percentages of poverty> 15% (46%),
with a low percentage of women from richest districts of the city par-
ticipated in this study. It must be noted that the distribution of public
health services is not homogeneous in the all districts of the city. High
rates of participation and follow-up in cancer screening programs are
usually mainly achieved in highest social strata [33–35]. However, our
results seem indicate that those may use alternative sectors of the
health system.
This study provides novel data from unvaccinated population in
Montevideo, which nucleate almost a half of the country population.
We found that both strategies used in cervical cancer screening, HPV
testing and cytology, identified the same risk factor for HSIL and high-
risk HPV infection, a high number of sexual partners. HPV testing also
identified housing conditions as risk factor for having a high-risk HPV
infection. Our results may help identifying risk groups of women that
could have a greater benefit from broadening the scope for prevention
of cervical cancer with HPV-screening, HPV-vaccination or a combi-
nation of both, and highlight the relevance of this baseline information
when formulating appropriate strategies towards cervical cancer con-
trol in the country. Moreover, our proposal of risk stratification of the
women according to different sociodemographic, sexual and re-
productive factors could be used as triage strategy, together with other
currently recommended or evaluated triage algorithms such as the use
of HPV genotype [36], methylation status [37,38] and p16 expression
[39].
Despite that, it had several limitations. Our work was not popula-
tion-based and thus, our results do not necessarily represent the level of
high-risk HPV infection and HSIL in the general female Uruguayan
population. The cross-sectional nature of the study design does not
allow for establishing a causal relationship of high-risk HPV infection or
HSIL with the cofactors investigated. In addition, self-administered
questionnaires can be subject to biases. Actually, the pattern showed for
the missing values of some sexual behavior variables (age at first in-
tercourse and pregnancy, number of sexual partners in the last year,
having a steady partner, and a history of sexual transmission disease)
can be interpreted as the questionnaire was not an appropriate tool to
explore sensitive matters in a conservative society with social taboos
about the topic. This problem was also observed in a similar Canadian
study with other cultural beliefs. [25]. However, the results from this
kind of surveys may indicate which groups of women are susceptible to
have a greater benefit from other existing strategies for cervical cancer
control. Finally, the absence of robustness in data on some risk factors
hampered their full assessment.
5. Conclusions
Our study provides a comprehensive description of factors asso-
ciated with high-risk HPV infection and HSIL among unvaccinated
women in Montevideo, using detailed information from an opportu-
nistic sample. Our results are valuable from a public health perspective,
since it can help to target groups which can get greater benefits from
health programs. The identification of the risk factors is also required to
adequately interpret associations with potential to selection bias in
epidemiologic studies. These baseline data may be useful to assess the
impact of the recently implemented national HPV vaccination program
and the whole new reforms in the Uruguayan public health system [13].
Moreover, in an era of development of new strategies for accelerating
the reduction of cervical cancer incidence and mortality, our results
may contribute to identify populations most susceptible to get benefit
from broadening the scope for prevention of cervical cancer and could
V.-G. Sequera et al. Papillomavirus Research 5 (2018) 122–127
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be used in combination with other currently recommended or evaluated
triage strategies.
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